Comparison of the Anesthetic Efficacy of Oliceridine and Sufentanil for General Anesthesia in Patients Undergoing Pulsed Field Ablation for Atrial Fibrillation: A Propensity Score-Matched Retrospective Cohort Study

Imagine your heart as a busy, high-speed train station. Sometimes, the tracks get crossed, and the trains (your heartbeats) start racing chaotically instead of following a steady rhythm. This is called atrial fibrillation, a common condition that can lead to serious trouble if the "trains" don't get sorted out. To fix this, doctors use a cool new tool called "Pulsed Field Ablation" (PFA). Think of PFA as a super-precise, non-thermal laser that zaps the bad tracks without burning anything nearby, getting the station back on schedule quickly.

However, before the doctors can do this delicate work, they have to put the patient to sleep. This is where the tricky part begins. Patients with heart issues often have "wobbly" engines; their hearts don't have much extra power to spare. The drugs used to put them to sleep are like heavy weights: they can calm the pain, but they can also accidentally push the heart's engine too hard, causing the blood pressure to drop dangerously low or the heart rate to slow down too much. For years, doctors have used a very strong, reliable drug called Sufentanil to manage the pain, but it's a bit of a "heavy lifter" that sometimes weighs down the heart too much. Recently, a new drug called Oliceridine arrived on the scene. It's designed to be a "smart weight"—it lifts the pain just as well but tries to leave the heart's engine alone. The big question for the medical team was: Can this new smart drug keep the heart stable better than the old reliable one during this specific heart repair?

This study, conducted by researchers at Rizhao Hospital, set out to find the answer by looking back at real patients who had this heart repair surgery. They compared two groups of people: one group got the new Oliceridine drug, and the other got the traditional Sufentanil. To make sure the comparison was fair, they used a clever statistical trick called "propensity score matching," which is like sorting a deck of cards so that every player in one hand has a perfect twin in the other hand regarding their age, weight, and heart health. After this sorting, they analyzed 142 patients (71 in each group) to see how their hearts reacted when the anesthesia was first turned on.

The results showed that the new drug, Oliceridine, was indeed the "lighter" and more stable choice. When the anesthesia was first given, the patients in the Oliceridine group kept their blood pressure and heart rate much steadier than those in the Sufentanil group. Specifically, five minutes after the drugs were given, the Oliceridine group had significantly higher average blood pressure (around 90.2 mmHg) compared to the Sufentanil group (around 81.5 mmHg). This stability meant that fewer patients needed emergency "boosters" like adrenaline or atropine to keep their hearts pumping strong; in fact, the Oliceridine group used significantly less of these rescue drugs.

Beyond just keeping the heart steady, the Oliceridine group woke up a little faster. On average, they opened their eyes about 6.3% sooner (4.5 minutes vs. 4.8 minutes) and were ready to leave the special heart lab about 8.9% faster (22.6 minutes vs. 24.8 minutes) than the Sufentanil group. While these time differences might sound small, the researchers noted that in a busy hospital, saving even a couple of minutes per patient adds up to huge efficiency gains. Interestingly, the pain relief was exactly the same for both groups; the new drug didn't sacrifice comfort for stability. The study also found that the Oliceridine group had fewer side effects like nausea or low blood pressure during the surgery and showed slightly less stress on their liver enzymes afterward.

The authors suggest that this new drug is a safer option, especially for patients with more severe heart conditions or those with a specific type of heart rhythm problem called "persistent atrial fibrillation," where the heart's reserve is even lower. However, they are careful to note that this was a single-center study looking at past records, not a brand-new experiment where they randomly assigned patients. While the results are promising and the data looks solid, the researchers say that larger, future studies are needed to confirm these findings across different hospitals. They aren't saying the old drug is "bad"—it still works well for many—but for patients with fragile hearts, Oliceridine appears to be the gentler, more stable ride.